Avia Pharma strengthens its position in medical self-care and dermatology through the acquisition of Allderma

STOCKHOLM, Sweden, 2 March 2026
Avia Pharma AB (“Avia”), a Sweden‑based pharmaceutical company focusing on OTC products across Northern Europe, today announced that it has completed the acquisition of the Swedish consumer health company Allderma AB (“Allderma”). The transaction closed on 27 February 2026 and represents another important step in Avia’s strategy to expand its presence within medically positioned consumer health and dermatology.

Iron supplement with new IHAT technology launched in Sweden and Finland

STOCKHOLM, Sweden, 2 December 2025
Tolfer is a new iron supplement developed for people with increased iron needs who experience gastrointestinal discomfort from certain traditional iron salts, such as ferrous sulfate. The product is now being launched in Sweden and Finland by Avia Pharma, and is based on the patented IHAT™ technology (Iron Hydroxide Adipate Tartrate) – designed to mimic how iron from food is absorbed and to reduce stomach-related discomfort.

Avia Pharma launches Oralmedic in the Nordics

STOCKHOLM, Sweden, 9 June 2025
Avia Pharma is expanding its self-care portfolio with the launch of Oralmedic, a fast and effective treatment for mouth ulcers, across the Nordic region…

Avia Pharma welcomes Impilo as a new partner

STOCKHOLM, Sweden, 2 February 2024
During January, Avia Pharma Holding AB (“Avia” or the “Company”), welcomed Impilo AB as a new owner and partner to the co-founders…

ACO Vitamin D acquisition

STOCKHOLM, Sweden, 15 June 2023
Avia Pharma has today completed the acquisition of ACO Vitamin D water and will as the new marketing authorisation holder re-launch the pharmaceutical in the Swedish market in Q4 this year…

Nyvigan launch in Swedish pharmacies

STOCKHOLM, Sweden, 1 February 2023
Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida…